Technology area: Medical Devices & Mechanical Engineering
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Isola Therapeutics Inc. currently manages 3 pending office actions within the Medical Devices & Mechanical Engineering technology area. These actions are assigned to 3 distinct examiners, yet they are all concentrated within 1 distinct art unit. This unique distribution suggests that while the company is interacting with multiple examiners, its current patenting activity is focused on a very specific technical niche within the medical device field.
EMILY LOUISE SCHMIDT is identified as the busiest examiner for the company, currently handling 1 pending office action. This 1 busiest examiner pending action is among the total 3 pending office actions in the portfolio. Because all 3 pending actions are located within 1 distinct art unit, the company may benefit from a consistent set of art unit standards even as it navigates the different perspectives of 3 distinct examiners. This concentration in 1 distinct art unit simplifies the technical scope of the prosecution effort.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, EMILY LOUISE | 1 | 58.4% | +36.6% |
| BRANDT, DAVID NELSON | 1 | 70.4% | +49.7% |
| TAYLOR, MARISSA ENVENESIA | 1 | 77.4% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18680666 | INTRALUMINAL LOCAL DRUG DELIVERY | SCHMIDT, EMILY LOUISE | — |
| 18444169 | DEVICES AND SYSTEMS FOR INTRALUMINAL LOCAL DRUG DELIVERY | BRANDT, DAVID NELSON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795344 | TISSUE DOSING FOR INTRALUMINAL LOCAL DRUG DELIVERY | TAYLOR, MARISSA ENVENESIA | 22d |
| 18680666 | INTRALUMINAL LOCAL DRUG DELIVERY | SCHMIDT, EMILY LOUISE | — |
| 18444169 | DEVICES AND SYSTEMS FOR INTRALUMINAL LOCAL DRUG DELIVERY | BRANDT, DAVID NELSON | — |
| Art Unit | Apps |
|---|---|
| 3783 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18680666 | INTRALUMINAL LOCAL DRUG DELIVERY | SCHMIDT, EMILY LOUISE | 3783 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18444169 | DEVICES AND SYSTEMS FOR INTRALUMINAL LOCAL DRUG DELIVERY | BRANDT, DAVID NELSON | 3783 | §103§112Other | Non-Final OA | — | Pending | Feb 16, 2024 |
| 17795344 | TISSUE DOSING FOR INTRALUMINAL LOCAL DRUG DELIVERY | TAYLOR, MARISSA ENVENESIA | 3783 | §103 | Final Rejection | 22d | Pending | Jul 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIsola Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Emily Louise Schmidt has the most, with 1 of Isola Therapeutics Inc.'s pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
